Unraveling risk factors and transcriptomic signatures in liver cancer progression and mortality through machine learning and bioinformatics
Asa TA., Hossain MA., Ali MS., Mahmud MZ., Azad AKM., Rahman MZ.
Cohort Study, published in Brief Funct Genomics (2026) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Cohort Study
- Journal
- Brief Funct Genomics (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41511815
- PMCID
- PMC12785888
- DOI
- 10.1093/bfgp/elaf019
Abstract (original English)
Liver cancer (LC) is the second leading cause of cancer-related deaths globally, yet the molecular mechanisms linking its progression with associated risk factors (RFs) remain poorly understood. To address this, we developed an integrative multi-stage framework combining bioinformatics, machine learning-based feature selection, survival modeling, and network analysis to identify robust biomarkers and pathways involved in LC progression. Unlike conventional biomarker discovery approaches, our strategy integrates multi-cohort transcriptomic and clinical datasets, enhancing robustness and reliability of findings. Initially, differentially expressed genes were identified from three Gene Expression Omnibus datasets for LC and its RFs. Next, using shared biomarkers, we constructed a gene-disease association (diseasome) network, revealing 230 unique genes, including 126 shared between LC and liver cirrhosis. Subsequently, RNA-seq and clinical data from The Cancer Genome Atlas (TCGA) were analyzed through combined and multivariate Cox survival models, identifying 70 prognostic genes. Among these, we identified RGS5, SULT1C2, CSM3, and CXCL14 as consistent survival-associated markers. Functional investigation of the 70 genes using enrichment and protein-protein interaction networks uncovered ten hub genes involved in key oncogenic pathways, including Oocyte meiosis, Lysine degradation a
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.